Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD 17.29
-0.51 (-2.84%)
Feb 12, 2026, 5:10 PM GMT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
1.31M GBP
Profits / Employee
-147.22K GBP
Market Cap
1.34B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Spire Healthcare Group | 15,703 |
| CVS Group | 8,850 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,780 |
Sarepta Therapeutics News
- 8 days ago - Sarepta (SRPT) Receives Green Light for Huntington's Disease Trial - GuruFocus
- 8 days ago - Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease - Business Wire
- 16 days ago - Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Concerns - GuruFocus
- 16 days ago - Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Today | SRPT Stock News - GuruFocus
- 16 days ago - Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow - Seeking Alpha
- 17 days ago - Sarepta Therapeutics Inc to Discuss 3-Year Topline Functional Results Transcript - GuruFocus
- 17 days ago - Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 17 days ago - Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday - Benzinga